CT Insurers Deny Adequate Coverage for Chronic Illness: The Impact on Patients
Background on Chronic Illness Coverage in CT
In Connecticut, an estimated 74,000 residents rely on high-cost biologics such as adalimumab to manage their chronic illnesses. Unfortunately, insurance companies often deny adequate coverage for these essential treatments, leaving patients in dire circumstances.
Impact of Coverage Denial
The ramifications of this lack of coverage are profound. Patients are increasingly forced to make the heartbreaking choice between their life-sustaining medications and other necessities such as rent and groceries.
Addressing the Issue
- Policy change is essential to ensure equitable access to vital treatments.
- Advocacy efforts are underway to highlight the need for reform.
- Engagement with healthcare policymakers will be crucial.
For those affected, the stakes are high. CT residents deserve better coverage and support for managing their chronic conditions.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.